New asthma drug AK139 enters phase 2 trial – hope for better lung function?
NCT ID NCT07436221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests a new drug called AK139 in 160 people with moderate to severe asthma. Participants receive either AK139 or a placebo by injection under the skin. The trial measures changes in lung function and asthma control over time, while also checking for side effects. It aims to see if AK139 can help manage asthma better than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK139 (a drug given by injection under the skin)
What this could lead to
If successful, this could lead to a new treatment option for people with moderate to severe asthma, helping to improve lung function and control symptoms.
What could go wrong
This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
Shanghai, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China